{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33497"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33497","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Public Preferences for Financing Disease-Modifying Alzheimer’s Therapies: Elicitation, Aggregation, and the Credibility of Beliefs","abstract":"Disease-modifying monoclonal antibodies for Alzheimer's disease, including lecanemab and donanemab, are under reimbursement review in Canada, raising financing decisions that cost-effectiveness analysis alone cannot resolve. This thesis examines public preferences for financing such therapies through three self-contained papers drawn from a single population-weighted survey of Ontario adults. The first paper measures what the public will collectively finance and how it believes the burden should be shared. Among 939 respondents, the population-weighted median voluntary contribution was $100 per year (95% CI $50–$100), and respondent-supported, majority-consistent revenue (approximately $1.16 billion under a uniform willingness-to-contribute schedule and $0.86 billion under a fairness-consistent schedule) exceeded projected per-adult program costs in every scenario examined; fair-tax allocations rose roughly twenty-fold across income brackets, indicating a systematic but bounded taste for progressivity. The second paper examines the structure beneath this aggregate. A latent class choice model of a private-financing discrete choice experiment recovers a two-class solution — a standard-trading majority (~89%) and a smaller minority (~11%) whose choices depart from standard demand patterns — and shows that willingness to pay is financing-contingent, so a single population estimate is an incomplete guide to policy. Class interpretation is disciplined using posterior inference of attitude–class relationships. The third paper interrogates the beliefs on which these valuations rest. Applying a probing elicitation framework (Giustinelli, Manski, and Molinari, 2022) to expectations about survival and Alzheimer's onset (N = 973), it finds that imprecise, interval-valued beliefs are the modal response on every outcome (49–60%), and that numeracy systematically predicts both response type and interval width. Together the papers advance a methodological position: credible preference evidence for policy requires measuring not only what people prefer, but who prefers it and how firmly the underlying beliefs are held.","abstract_html":"Disease-modifying monoclonal antibodies for Alzheimer&#x27;s disease, including lecanemab and donanemab, are under reimbursement review in Canada, raising financing decisions that cost-effectiveness analysis alone cannot resolve. This thesis examines public preferences for financing such therapies through three self-contained papers drawn from a single population-weighted survey of Ontario adults. The first paper measures what the public will collectively finance and how it believes the burden should be shared. Among 939 respondents, the population-weighted median voluntary contribution was $100 per year (95% CI $50–$100), and respondent-supported, majority-consistent revenue (approximately $1.16 billion under a uniform willingness-to-contribute schedule and $0.86 billion under a fairness-consistent schedule) exceeded projected per-adult program costs in every scenario examined; fair-tax allocations rose roughly twenty-fold across income brackets, indicating a systematic but bounded taste for progressivity. The second paper examines the structure beneath this aggregate. A latent class choice model of a private-financing discrete choice experiment recovers a two-class solution — a standard-trading majority (~89%) and a smaller minority (~11%) whose choices depart from standard demand patterns — and shows that willingness to pay is financing-contingent, so a single population estimate is an incomplete guide to policy. Class interpretation is disciplined using posterior inference of attitude–class relationships. The third paper interrogates the beliefs on which these valuations rest. Applying a probing elicitation framework (Giustinelli, Manski, and Molinari, 2022) to expectations about survival and Alzheimer&#x27;s onset (N = 973), it finds that imprecise, interval-valued beliefs are the modal response on every outcome (49–60%), and that numeracy systematically predicts both response type and interval width. Together the papers advance a methodological position: credible preference evidence for policy requires measuring not only what people prefer, but who prefers it and how firmly the underlying beliefs are held.","abstract_has_math":true,"creators":["von Schlegell, Ahmad"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Health Management","school":null,"contributors":[],"advisors":["Longo, Christopher"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:32:37Z","subjects":[],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/2281"],"render_values":[{"text":"https://doi.org/10.71548/2281","href":"https://doi.org/10.71548/2281","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33497","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33497","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33497","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Longo, Christopher"]},{"key":"dc:contributor.department","label":"Department","values":["Health Management"]},{"key":"dc:creator","label":"Author","values":["von Schlegell, Ahmad"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-08-25T17:51:03Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation","Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33497","https://doi.org/10.71548/2281"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["This thesis follows the \"sandwich\" format and comprises three self-contained papers, an introductory chapter, and a concluding chapter. The thesis was supervised by Dr. Christopher J. Longo, with Dr. Arthur Sweetman and Dr. Manaf Zargoush as supervisory committee members. The survey research underlying the thesis was conducted in close collaboration with Dr. Shaun Shaikh, and the survey's development further benefited from methodological and conceptual contributions by Dr. John F. P. Bridges, Dr. Charles Manski, Dr. Adeline Delavande, and Dr. Stephane Hess; authorship details are set out in the Declaration of Academic Achievement. All three papers are being prepared for journal submission, with co-authors on the journal versions expected to include Dr. Shaun Shaikh, Dr. John F. P. Bridges, Dr. Arthur Sweetman, Dr. Manaf Zargoush, Dr. Charles Manski, and Dr. Stephane Hess. All three papers draw on a single population-weighted survey of Ontario adults conducted in 2025–2026."]},{"key":"dc:description.abstract","label":"Abstract","values":["Disease-modifying monoclonal antibodies for Alzheimer's disease, including lecanemab and donanemab, are under reimbursement review in Canada, raising financing decisions that cost-effectiveness analysis alone cannot resolve. This thesis examines public preferences for financing such therapies through three self-contained papers drawn from a single population-weighted survey of Ontario adults. The first paper measures what the public will collectively finance and how it believes the burden should be shared. Among 939 respondents, the population-weighted median voluntary contribution was $100 per year (95% CI $50–$100), and respondent-supported, majority-consistent revenue (approximately $1.16 billion under a uniform willingness-to-contribute schedule and $0.86 billion under a fairness-consistent schedule) exceeded projected per-adult program costs in every scenario examined; fair-tax allocations rose roughly twenty-fold across income brackets, indicating a systematic but bounded taste for progressivity. The second paper examines the structure beneath this aggregate. A latent class choice model of a private-financing discrete choice experiment recovers a two-class solution — a standard-trading majority (~89%) and a smaller minority (~11%) whose choices depart from standard demand patterns — and shows that willingness to pay is financing-contingent, so a single population estimate is an incomplete guide to policy. Class interpretation is disciplined using posterior inference of attitude–class relationships. The third paper interrogates the beliefs on which these valuations rest. Applying a probing elicitation framework (Giustinelli, Manski, and Molinari, 2022) to expectations about survival and Alzheimer's onset (N = 973), it finds that imprecise, interval-valued beliefs are the modal response on every outcome (49–60%), and that numeracy systematically predicts both response type and interval width. Together the papers advance a methodological position: credible preference evidence for policy requires measuring not only what people prefer, but who prefers it and how firmly the underlying beliefs are held."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:description.sponsorship","label":"Dc Description Sponsorship","values":["I gratefully acknowledge the financial support of a SSHRC grant and the Alzheimer Society of Peel."]},{"key":"dc:title","label":"Title","values":["Public Preferences for Financing Disease-Modifying Alzheimer’s Therapies: Elicitation, Aggregation, and the Credibility of Beliefs"]},{"key":"others:access_status","label":"Others Access Status","values":["embargo"]}]}],"canonical_facts":{"dc:contributor.advisor":["Longo, Christopher"],"dc:contributor.department":["Health Management"],"dc:creator":["von Schlegell, Ahmad"],"dc:date.accessioned":["2026-08-25T17:51:03Z"],"dc:date.issued":["2026"],"dc:description":["This thesis follows the \"sandwich\" format and comprises three self-contained papers, an introductory chapter, and a concluding chapter. The thesis was supervised by Dr. Christopher J. Longo, with Dr. Arthur Sweetman and Dr. Manaf Zargoush as supervisory committee members. The survey research underlying the thesis was conducted in close collaboration with Dr. Shaun Shaikh, and the survey's development further benefited from methodological and conceptual contributions by Dr. John F. P. Bridges, Dr. Charles Manski, Dr. Adeline Delavande, and Dr. Stephane Hess; authorship details are set out in the Declaration of Academic Achievement. All three papers are being prepared for journal submission, with co-authors on the journal versions expected to include Dr. Shaun Shaikh, Dr. John F. P. Bridges, Dr. Arthur Sweetman, Dr. Manaf Zargoush, Dr. Charles Manski, and Dr. Stephane Hess. All three papers draw on a single population-weighted survey of Ontario adults conducted in 2025–2026."],"dc:description.abstract":["Disease-modifying monoclonal antibodies for Alzheimer's disease, including lecanemab and donanemab, are under reimbursement review in Canada, raising financing decisions that cost-effectiveness analysis alone cannot resolve. This thesis examines public preferences for financing such therapies through three self-contained papers drawn from a single population-weighted survey of Ontario adults. The first paper measures what the public will collectively finance and how it believes the burden should be shared. Among 939 respondents, the population-weighted median voluntary contribution was $100 per year (95% CI $50–$100), and respondent-supported, majority-consistent revenue (approximately $1.16 billion under a uniform willingness-to-contribute schedule and $0.86 billion under a fairness-consistent schedule) exceeded projected per-adult program costs in every scenario examined; fair-tax allocations rose roughly twenty-fold across income brackets, indicating a systematic but bounded taste for progressivity. The second paper examines the structure beneath this aggregate. A latent class choice model of a private-financing discrete choice experiment recovers a two-class solution — a standard-trading majority (~89%) and a smaller minority (~11%) whose choices depart from standard demand patterns — and shows that willingness to pay is financing-contingent, so a single population estimate is an incomplete guide to policy. Class interpretation is disciplined using posterior inference of attitude–class relationships. The third paper interrogates the beliefs on which these valuations rest. Applying a probing elicitation framework (Giustinelli, Manski, and Molinari, 2022) to expectations about survival and Alzheimer's onset (N = 973), it finds that imprecise, interval-valued beliefs are the modal response on every outcome (49–60%), and that numeracy systematically predicts both response type and interval width. Together the papers advance a methodological position: credible preference evidence for policy requires measuring not only what people prefer, but who prefers it and how firmly the underlying beliefs are held."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:description.sponsorship":["I gratefully acknowledge the financial support of a SSHRC grant and the Alzheimer Society of Peel."],"dc:identifier.uri":["https://hdl.handle.net/11375/33497","https://doi.org/10.71548/2281"],"dc:language.iso":["en_US"],"dc:title":["Public Preferences for Financing Disease-Modifying Alzheimer’s Therapies: Elicitation, Aggregation, and the Credibility of Beliefs"],"dc:type":["Dissertation","Thesis"],"others:access_status":["embargo"]},"updated_at":"2026-11-18T19:32:37Z"}